Skip to main content
Top
Published in: International Journal of Hematology 5/2013

01-05-2013 | Case Report

Development of peripheral T-cell lymphoma not otherwise specified in an HTLV-1 carrier

Authors: Tomohiro Ishigaki, Masamichi Isobe, Seiichiro Kobayashi, Koichiro Yuji, Nobuhiro Ohno, Nobukazu Watanabe, Arinobu Tojo, Kaoru Uchimaru

Published in: International Journal of Hematology | Issue 5/2013

Login to get access

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL) after a long latency period of about 60 years. As the mature T-cell neoplasms that emerge in patients infected with HTLV-1 are often ATL, T-cell neoplasms developing in such patients tend to be diagnosed simply as ATL without further investigation. However, not all T-cell neoplasms that develop in HTLV-1-infected cases are ATL. Mature T-cell malignancies other than ATL should be carefully excluded in patients infected with HTLV-1, as these sometimes closely resemble ATL in their clinical, morphological, and histological features. Here, we present a case of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) in an HTLV-1 carrier. Confirmation of monoclonal integration of the virus with Southern blotting leads to a definite diagnosis of ATL. Although we did not detect the monoclonal integration band of HTLV-1 in this case, the high HTLV-1 proviral load complicated the diagnosis. Multicolor flow cytometric analysis clearly showed that HTLV-1 was not integrated in the tumor cells, and facilitated discrimination of PTCL-NOS from ATL.
Literature
1.
go back to reference Matsumoto M, Nomura K. Clinical and hematological features of adult T cell leukemia in southern part of Kyushu, Japan (author’s transl). Rinsho Ketsueki. 1979;20:1040–7.PubMed Matsumoto M, Nomura K. Clinical and hematological features of adult T cell leukemia in southern part of Kyushu, Japan (author’s transl). Rinsho Ketsueki. 1979;20:1040–7.PubMed
2.
go back to reference Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031–5.PubMedCrossRef Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031–5.PubMedCrossRef
3.
go back to reference Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79:428–37.PubMedCrossRef Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79:428–37.PubMedCrossRef
4.
go back to reference Ishitsuka K, Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol. 2008;80:185–96.PubMedCrossRef Ishitsuka K, Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol. 2008;80:185–96.PubMedCrossRef
5.
go back to reference Nakano-Akamatsu S, Takahashi R, Sekioka Y, et al. CD20- and CD56-positive T-cell large granular lymphocyte leukemia in a human T-cell leukemia virus type 1 carrier. Int J Hematol. 2007;86:348–51.PubMedCrossRef Nakano-Akamatsu S, Takahashi R, Sekioka Y, et al. CD20- and CD56-positive T-cell large granular lymphocyte leukemia in a human T-cell leukemia virus type 1 carrier. Int J Hematol. 2007;86:348–51.PubMedCrossRef
6.
go back to reference Ohmatsu H, Sugaya M, Fujita H, et al. Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma in a human T-cell leukaemia virus type-1 carrier. Acta Derm Venereol. 2010;90:324–5.PubMed Ohmatsu H, Sugaya M, Fujita H, et al. Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma in a human T-cell leukaemia virus type-1 carrier. Acta Derm Venereol. 2010;90:324–5.PubMed
7.
go back to reference Chuang SS, Ichinohasama R, Chu JS, et al. Differential diagnosis of angioimmunoblastic T-cell lymphoma with seropositivity for anti-HTLV antibody from adult T-cell leukemia/lymphoma. Int J Hematol. 2010;91:687–91.PubMedCrossRef Chuang SS, Ichinohasama R, Chu JS, et al. Differential diagnosis of angioimmunoblastic T-cell lymphoma with seropositivity for anti-HTLV antibody from adult T-cell leukemia/lymphoma. Int J Hematol. 2010;91:687–91.PubMedCrossRef
8.
go back to reference Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211–9.PubMedCrossRef Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211–9.PubMedCrossRef
9.
go back to reference Ohshima K. Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci. 2007;98:772–8.PubMedCrossRef Ohshima K. Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci. 2007;98:772–8.PubMedCrossRef
10.
go back to reference Kamihira S, Atogami S, Sohda H, et al. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer. 1994;73:2753–8.PubMedCrossRef Kamihira S, Atogami S, Sohda H, et al. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer. 1994;73:2753–8.PubMedCrossRef
11.
go back to reference Tian Y, Kobayashi S, Ohno N, et al. Leukemic T cells are specifically enriched in a unique CD3(dim) CD7(low) subpopulation of CD4(+) T cells in acute-type adult T-cell leukemia. Cancer Sci. 2011;102:569–77.PubMedCrossRef Tian Y, Kobayashi S, Ohno N, et al. Leukemic T cells are specifically enriched in a unique CD3(dim) CD7(low) subpopulation of CD4(+) T cells in acute-type adult T-cell leukemia. Cancer Sci. 2011;102:569–77.PubMedCrossRef
12.
go back to reference Kobayashi S, Tian Y, Ohno N, et al. The CD3 versus CD7 plot in multicolor flow cytometry reflects progression of disease stage in patients infected with HTLV-I. PLoS ONE. 2013;8:e53728.PubMedCrossRef Kobayashi S, Tian Y, Ohno N, et al. The CD3 versus CD7 plot in multicolor flow cytometry reflects progression of disease stage in patients infected with HTLV-I. PLoS ONE. 2013;8:e53728.PubMedCrossRef
13.
go back to reference Asou N, Kumagai T, Uekihara S, et al. HTLV-I seroprevalence in patients with malignancy. Cancer. 1986;58:903–7.PubMedCrossRef Asou N, Kumagai T, Uekihara S, et al. HTLV-I seroprevalence in patients with malignancy. Cancer. 1986;58:903–7.PubMedCrossRef
14.
go back to reference Kozuru M, Uike N, Muta K, et al. High occurrence of primary malignant neoplasms in patients with adult T-cell leukemia/lymphoma, their siblings, and their mothers. Cancer. 1996;78:1119–24.PubMedCrossRef Kozuru M, Uike N, Muta K, et al. High occurrence of primary malignant neoplasms in patients with adult T-cell leukemia/lymphoma, their siblings, and their mothers. Cancer. 1996;78:1119–24.PubMedCrossRef
15.
go back to reference Suefuji H, Ohshima K, Hayabuchi N, et al. HTLV-1 carriers with B-cell lymphoma of localized stage head and neck: prognosis, clinical and immunopathological features. Br J Haematol. 2003;123:606–12.PubMedCrossRef Suefuji H, Ohshima K, Hayabuchi N, et al. HTLV-1 carriers with B-cell lymphoma of localized stage head and neck: prognosis, clinical and immunopathological features. Br J Haematol. 2003;123:606–12.PubMedCrossRef
16.
go back to reference Sugata K, Satou Y, Yasunaga JI, et al. HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines. Blood. 2012;119(2):434–44. Sugata K, Satou Y, Yasunaga JI, et al. HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines. Blood. 2012;119(2):434–44.
17.
go back to reference Imaizumi Y, Tsukasaki K, Tsushima H, et al. Lymphoma cases without detectable monoclonal HTLV-1 integration in HTLV-1 carrier. Rinsho Ketsueki. 2012;53:1359. Imaizumi Y, Tsukasaki K, Tsushima H, et al. Lymphoma cases without detectable monoclonal HTLV-1 integration in HTLV-1 carrier. Rinsho Ketsueki. 2012;53:1359.
18.
go back to reference Lotan I, Khlebtovsky A, Inbar E, et al. Primary brain T-cell lymphoma in an HTLV-1 serologically positive male. J Neurol Sci. 2012;314:163–5.PubMedCrossRef Lotan I, Khlebtovsky A, Inbar E, et al. Primary brain T-cell lymphoma in an HTLV-1 serologically positive male. J Neurol Sci. 2012;314:163–5.PubMedCrossRef
Metadata
Title
Development of peripheral T-cell lymphoma not otherwise specified in an HTLV-1 carrier
Authors
Tomohiro Ishigaki
Masamichi Isobe
Seiichiro Kobayashi
Koichiro Yuji
Nobuhiro Ohno
Nobukazu Watanabe
Arinobu Tojo
Kaoru Uchimaru
Publication date
01-05-2013
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2013
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-013-1314-z

Other articles of this Issue 5/2013

International Journal of Hematology 5/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine